REFERENCES

1. Orzetti S, Tommasi F, Bertola A, et al. Genetic therapy and molecular targeted therapy in oncology: safety, pharmacovigilance, and perspectives for research and clinical practice. Int J Mol Sci 2022;23:3012.

2. World Health Organization. The importance of pharmacovigilance. Available from: https://www.who.int/publications-detail-redirect/10665-42493 [Last accessed on 20 Nov 2023].

3. Kugener VF, Freedland ES, Maynard KI, et al. Enhancing pharmacovigilance from the US experience: current practices and future opportunities. Drug Saf 2021;44:843-52.

4. EMA European Medicine Agency. Good pharmacovigilance practices. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices#final-gvp-annex-i---definitions-section [Last accessed on 20 Nov 2023].

5. EMA European Medicine Agency. Guideline on good pharmacovigilance practices (GVP) module XV - safety communication (Rev 1). Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-rev-1_en.pdf [Last accessed on 20 Nov 2023].

6. EMA. How the committees work. Available from: https://www.ema.europa.eu/en/committees/how-committees-work [Last accessed on 20 Nov 2023].

7. EMA European Medicine Agency. Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products-scientific guideline. Available from: https://www.ema.europa.eu/en/guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-scientific [Last accessed on 20 Nov 2023].

8. EMA European Medicine Agency. Guideline on follow-up of patients administered with gene therapy medicinal products. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf [Last accessed on 20 Nov 2023].

9. EMA European Medicine Agency. Reflection paper on quality, non-clinical and clinical issues related to the development of recombinant adenoassociated viral vectors. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-quality-non-clinical-clinical-issues-related-development-recombinant-adeno_en.pdf [Last accessed on 20 Nov 2023].

10. EMA European Medicine Agency. Reflection paper on management of clinical risks deriving from insertional mutagenesis. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-management-clinical-risks-deriving-insertional-mutagenesis_en.pdf [Last accessed on 20 Nov 2023].

11. David RM, Doherty AT. Viral vectors: the road to reducing genotoxicity. Toxicol Sci 2017;155:315-25.

12. Aiuti A, Cossu G, de Felipe P, et al. The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis. Hum Gene Ther Clin Dev 2013;24:47-54.

13. Wagner EF, Covarrubias L, Stewart TA, Mintz B. Prenatal lethalities in mice homozygous for human growth hormone gene sequences integrated in the germ line. Cell 1983;35:647-55.

14. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363:355-64.

15. Riggan KA, Nyquist C, Michie M, Allyse MA. Evaluating the risks and benefits of genetic and pharmacologic interventions for down syndrome: views of parents. Am J Intellect Dev Disabil 2020;125:1-13.

16. Day JW, Mendell JR, Mercuri E, et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf 2021;44:1109-19.

17. Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther 2018;29:285-98.

18. Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol 2021;74:560-6.

19. Feldman AG, Parsons JA, Dutmer CM, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr 2020;225:252-8.e1.

20. NOVARTIS. Zolgensma acute liver failure update. Available from: https://www.novartis.com/news/zolgensma-acute-liver-failure-update [Last accessed on 20 Nov 2023].

21. EMA European Medicine Agency. Pharmacovigilance risk assessment committee (PRAC) PRAC minutes on 08-11 March 2021. Available from: https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-march-2021_en.pdf [Last accessed on 20 Nov 2023].

22. EMA European Medicine Agency. Zynteglo withdrawal of the marketing authorisation in the European Union. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-zynteglo-withdrawal-marketing-authorisation-european-union_en.pdf [Last accessed on 20 Nov 2023].